Infection with SARS-CoV-2 may alter the half-life of desmopressin (DDAVP) in patients with central diabetes insipidus.
J Pediatr Endocrinol Metab
; 35(12): 1544-1546, 2022 Dec 16.
Article
in English
| MEDLINE | ID: covidwho-2079806
ABSTRACT
We present a 9-year-old boy with diabetes insipidus. The boy is treated with desmopressin (DDAVP) therapy. Under this therapy, the drinking quantity and the laboratory parameters were normal. No nocturia occurred any more. In the context of a clinically mild infection with SARS-CoV-2, the duration of action of DDAVP was significantly prolonged (approximately +50%). The original dosage was then reintroduced and was still sufficient until months later. A possible connection to the infection with SARS-CoV-2 can be suspected. Our case report should make physicians who care for patients with diabetes insipidus aware of such a possible prolongation of the effect of DDAVP. More frequent monitoring may be needed in such patients to assess the risk of symptomatic dilutional hyponatremia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Diabetes Insipidus, Neurogenic
/
Diabetes Insipidus
/
Diabetes Mellitus
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Prognostic study
Topics:
Long Covid
Limits:
Child
/
Humans
/
Male
Language:
English
Journal:
J Pediatr Endocrinol Metab
Journal subject:
Endocrinology
/
Pediatrics
Year:
2022
Document Type:
Article
Affiliation country:
Jpem-2022-0422
Similar
MEDLINE
...
LILACS
LIS